PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial
PD-1抗体卡瑞利珠单抗联合阿帕替尼和SOX方案作为一线治疗AFP阳性胃癌或胃食管交界处腺癌患者的疗效(CAP 06):一项多中心、单臂II期临床试验
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02193-z
Wang, Yakun; Lu, Jialin; Chong, Xiaoyi; Wang, Chang; Chen, Xiaofeng; Peng, Zhi; Gu, Yanhong; Wang, Yizhuo; Wang, Xicheng; Li, Jian; Gong, Jifang; Qi, Changsong; Yuan, Jiajia; Lu, Zhihao; Lu, Ming; Zhou, Jun; Cao, Yanshuo; Chen, Yang; Zhang, Cheng; Hou, Zhiguo; Kou, Hongyi; Shen, Lin; Zhang, Xiaotian